FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to methods of treating a malignant tumor in an individual in need thereof, involving: (a) administering to an individual an effective amount of pegylated trimeric H-NOX protein, wherein the pegylated trimeric H-NOX protein contains three monomers, wherein each monomer comprises a H-NOX domain and a trimerisation domain and wherein the H-NOX domain is an H-NOX domain Thermoanaerobacter tengcongensis (“T. tengcongensis”), comprising an amino acid substitution L144F in a distal pocket; and (b) immunotherapy of an individual.
EFFECT: such methods are suitable for treating a wide range of malignant tumors.
78 cl, 8 ex, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
